Apollo Endosurgery to Present at HC Wainwright Global Life Sciences Conference
Apollo Endosurgery, Inc. (NASDAQ:APEN) will participate in the virtual H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apollo Endosurgery, Inc. (NASDAQ:APEN) will participate in the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. Management, including CEO Chas McKhann and CFO Stefanie Cavanaugh, will provide a pre-recorded presentation and be available for one-on-one meetings with investors. Apollo specializes in less invasive medical devices for gastrointestinal and bariatric procedures, marketing its products in over 75 countries. For further information, contact the investor relations team.
Details
News Market Reaction – APEN
The recorded move for APEN in the trading session of this news was -3.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, TX / ACCESSWIRE / March 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it will participate in the H.C. Wainwright Global Life Sciences Conference taking place virtually March 9-10, 2021.
Management will provide a pre-recorded presentation which will be available to registered investors on demand via the conference website. As part of the conference agenda, Chief Executive Officer Chas McKhann and Chief Financial Officer Stefanie Cavanaugh will be available for one on one meetings with investors.
For more information about the conference or to arrange a meeting, please contact your H.C. Wainwright representative or Matt Kreps, Investor Relations for Apollo Endosurgery, at mkreps@darrowir.com.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on the development of next-generation, less invasive devices to advance gastrointestinal therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, X-TackTM Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon.
Apollo's common stock is traded on NASDAQ Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.
Contact:
Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
investor-relations@apolloendo.com
Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com
SOURCE: Apollo Endosurgery, Inc.
View source version on accesswire.com:
https://www.accesswire.com/632991/Apollo-Endosurgery-to-Present-at-HC-Wainwright-Global-Life-Sciences-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.